Novocure Advances Tumor Treating Fields Technology For Patients With Newly Diagnosed Glioblastoma

Novocure’s tumor treating fields technology offers hope to the 10,000 to 12,000 patients in the US diagnosed with glioblastoma multiforme (GBM), the most common and deadliest form of malignant primary brain tumor. The EF-14 Phase III clinical trial evaluating the company’s Optune device for newly diagnosed GBM was terminated due to early success, and in December 2014, the FDA approved an IDE supplement allowing all control patients in the trial to receive the treatment.